Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Noveko International Inc T.EKO



TSX:EKO - Post by User

Bullboard Posts
Comment by toomuchon Aug 28, 2007 2:17pm
222 Views
Post# 13311794

RE: Halted....Look to see reason

RE: Halted....Look to see reason2007 14:15 ET 'Noveko International Inc. gets the green light to market its antimicrobial face masks in Canada ' - CNW Health Canada issues establishment licence to Noveko Inc. ------------------------------------------------------------------------ (EKO-TSX Venture Exchange) MONTREAL, Aug. 28 /CNW Telbec/ - NOVEKO INTERNATIONAL INC. ("Noveko" or "the Company") announces that its subsidiary Noveko Inc. has been granted an establishment licence by Health Canada and can now begin marketing its 3xEZ (surgical mask) and its 5dEZR (surgical respirator) face masks in Canada. These face masks are derivative products from Noveko's patented antimicrobial technology and provide 100% bioprotection (superior to N-99-approved products), while facilitating breathing and offering more comfortable skin contact than any other face mask currently on the market. "We are very pleased that Health Canada has issued an establishment licence to our subsidiary Noveko Inc., thereby kickstarting the marketing of our antimicrobial face masks for health institutions (hospitals, medical clinics, dental clinics, etc.), medical bodies, government organizations, civil relief units and the general public, notably in the event of pandemics considering our face masks' superior protection," indicated Alain Bolduc, President and Chief Operating Officer of Noveko. Mr. Bolduc specified that: "Noveko Inc. has already set up its complete face mask production chain through Canadian, U.S. and Asian companies. Furthermore, Noveko has sufficient inventory to shortly launch its antimicrobial face masks on the Canadian market." The North American mask market represents annual sales of approximately US$800 million, of which the Canadian market accounts for some US$200 million, and the global market totals approximately US$8 billion. With its unique antimicrobial technology, which has given rise to a new generation of face masks providing the necessary protection against bacteria and viruses and contributing to prevent pandemics, Noveko Inc. intends to become an active player in this market. It will do so through medical product distribution networks, by setting up a sales force and by entering into alliances with manufacturers. Noveko Inc. is also targeting other geographic markets, including the United States, various Asian and Eurasian markets, Europe and Africa. In addition to the U.S. patent delivered by the United States Patent and Trademark Office (May 2006), Noveko's antimicrobial technology has been patented by the Eurasian Patent Office, located in Moscow (July 2007), and the Company has similar international patents pending. Profile of Noveko International Inc. ------------------------------------ Noveko International Inc. currently has four subsidiaries: S.A.S. ECM, Noveko Inc., Laboratoire SyMa Inc. ("SyMa") and Bolduc Leroux Inc. (BLI). ECM specializes in the design and marketing of portable real-time ultrasound scanners for use in veterinary and human medicine. Noveko Inc. develops the Company's biomedical and environmental business, specifically its patented antimicrobial filtration technology and derivative products (antimicrobial face masks and air filters). SyMa specializes in the manufacture of sanitizers, more specifically the antimicrobial products (for hands, feet and surfaces) sold under the Azuro trademark. For its part, BLI specializes in the custom processing and distribution of steel products based on client specifications and designs. It has also developed and markets a line of downdraft particle extraction tables for various industrial, commercial and pharmaceutical markets. Operating since September 2002, the Company was listed on the TSX Venture Exchange on February 3, 2004. The information set forth in this press release includes certain forward-looking statements. Such statements are based on assumptions exposed to major risks and uncertainties. Although Noveko deems the expectations reflected in these forward-looking statements to be reasonable, the Company cannot provide any guarantee as to the materialization of the expectations reflected in these forward-looking statements. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. For further information: Andre Leroux, Chairman of the Board and Chief Executive Officer, (514) 344-3030; Alain Bolduc, President and Chief Operating Officer, (514) 344-3030, https://www.noveko.com; Marie-Claude Leroux, Morin Public Relations, (514) 289-8688, ext. 224, Cell: (514) 705-5897, marieclaude@morinrp.com
Bullboard Posts